These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prolongation of xenograft survival by soluble complement receptor type 1 and antithrombin-III combination therapy. Fujiwara I; Nakajima H; Arakawa K; Akioka K; Takeshita K; Oka T Transplant Proc; 1996 Apr; 28(2):685-6. PubMed ID: 8623345 [No Abstract] [Full Text] [Related]
11. Retinoic acid inhibits expression of E-selectin in endothelial cells and prolongs discordant xenograft survival. Blakely ML; Van der Werf WJ; Stuhlmeier K; Dalmasso AP; Winkler H; Bach FH Transplant Proc; 1994 Jun; 26(3):1176. PubMed ID: 7518108 [No Abstract] [Full Text] [Related]
12. Soluble complement receptor type 1 and antithrombin-III combination therapy prolongs xenograft survival: the role of thrombin and prostacyclin in hyperacute rejection. Fujiwara I; Nakajima H; Akioka K; Matsuda T; Oka T Transplant Proc; 1997; 29(1-2):935-7. PubMed ID: 9123594 [No Abstract] [Full Text] [Related]
13. Effectiveness of adenovirus-mediated gene transfer with CTLA4Ig in allo and xeno-transplantation. Hayashi S; Dai-Kaku L; Namii Y; Kato T; Tokoro T; Kobayashi T; Yokoyama I; Hamada H; Nakao A Transplant Proc; 2000 Nov; 32(7):2520-1. PubMed ID: 11120276 [No Abstract] [Full Text] [Related]
14. Long-term survival of heart and liver xenografts with splenectomy and FK 506. Celli S; Valdivia LA; Fung JJ; Demetris AJ; Marino IR; Murase N; Starzl TE Transplant Proc; 1993 Feb; 25(1 Pt 1):647-8. PubMed ID: 7679830 [TBL] [Abstract][Full Text] [Related]
15. Operational tolerance of long-surviving cardiac xenografts (LSCX) is related to modification of the graft-in-residence and not to induced tolerance in the recipient: studies in retransplanted LSCX. Thomas F; Quarantillo P; Contreras J; Thomas J Transplant Proc; 1999; 31(1-2):966-7. PubMed ID: 10083430 [No Abstract] [Full Text] [Related]
16. The histopathologic appearance of rejected xenografts in a neovascularized and primarily vascularized rodent system. Fischel RJ; King NJ; Manivel C; Almond SP; Chen S; Bolman RM; Matas AJ Transplant Proc; 1992 Apr; 24(2):631. PubMed ID: 1373545 [No Abstract] [Full Text] [Related]
17. Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival. Stevens RB; Wang YL; Kaji H; Lloveras J; Dalmasso A; Bach FH; Rubinstein P; Sutherland DE; Platt JL Transplant Proc; 1993 Feb; 25(1 Pt 1):382. PubMed ID: 8438344 [No Abstract] [Full Text] [Related]
18. Prolongation of discordant cardiac xenotransplantation survival by Lisofylline, a phosphatidic acid inhibitor. Aziz S; Suzuki K; Rice G; Reichenbach DD Transplant Proc; 1996 Apr; 28(2):740. PubMed ID: 8623375 [No Abstract] [Full Text] [Related]
19. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Enjyoji K; Sévigny J; Lin Y; Frenette PS; Christie PD; Esch JS; Imai M; Edelberg JM; Rayburn H; Lech M; Beeler DL; Csizmadia E; Wagner DD; Robson SC; Rosenberg RD Nat Med; 1999 Sep; 5(9):1010-7. PubMed ID: 10470077 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment of recipients (nude rat) with donor antigens leads to prolonged survival of hamster heart xenografts. Tsugita M; Rao AS; Sun H; Wakizaka Y; Madariaga J; Pan F; Demetris AJ; Fung JJ; Starzl TE; Valdivia LA Transplant Proc; 1996 Apr; 28(2):696-7. PubMed ID: 8623351 [No Abstract] [Full Text] [Related] [Next] [New Search]